{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:58:50Z","timestamp":1790935130545,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ekir.2026.107000","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:27:41Z","timestamp":1785565661000},"page":"107000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward a Treatment Goal Framework for Emerging Therapies in IgAN: Implications for Future Research"],"prefix":"10.1016","volume":"11","author":[{"given":"Muh Geot","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Maski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lafayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.107000_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2026.03.003","article-title":"Complement inhibitors and B cell-modifying agents for IgA nephropathy-a Kidney Disease: improving Global Outcomes (KDIGO) commentary","author":"Rovin","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107000_bib2","article-title":"The role of BAFF and April in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2023","journal-title":"Front Nephrol"},{"key":"10.1016\/j.ekir.2026.107000_bib3","article-title":"Therapy of IgA nephropathy: time for a paradigm change","volume":"11","author":"Barratt","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2026.107000_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.107000_bib5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ekir.2025.10.029","article-title":"Povetacicept for IgA nephropathy and primary membranous nephropathy","volume":"11","author":"Madan","year":"2026","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.107000_bib6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.107000_bib7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2021.03.007","article-title":"Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.107000_bib8","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2026.107000_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/j.ajkd.2026.02.649","article-title":"Hematuria remission and prognosis in IgA nephropathy: a post hoc analysis of the TESTING randomized clinical trial","volume":"88","author":"Wu","year":"2026","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.107000_bib10","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926032328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926032328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:43:20Z","timestamp":1790934200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926032328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2468024926032328"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.107000","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward a Treatment Goal Framework for Emerging Therapies in IgAN: Implications for Future Research","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.107000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"107000"}}